Company BioNTech SE BOERSE MUENCHEN

Equities

22UA

US09075V1026

Biotechnology & Medical Research

Real-time BOERSE MUENCHEN 01:14:31 16/05/2024 am IST 5-day change 1st Jan Change
84.65 EUR -0.41% Intraday chart for BioNTech SE +0.06% -10.66%

Business Summary

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Sales per Business

USD in Million2022Weight2023Weight Delta
Immunotherapy Technologies
100.0 %
18,193 100.0 % 4,129 100.0 % -77.31%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
78.8 %
13,358 73.4 % 3,255 78.8 % -75.63%
Germany
12.6 %
3,186 17.5 % 522 12.6 % -83.62%
International
8.8 %
1,488 8.2 % 362 8.8 % -75.70%
Turkey
-0.2 %
162 0.9 % -10 -0.2 % -106.09%

Managers

Managers TitleAgeSince
Chief Executive Officer 58 02/08/02
Founder 57 02/08/02
Director of Finance/CFO 60 01/21/01
Chief Operating Officer 51 01/14/01
Chief Operating Officer 59 -
Investor Relations Contact - -
General Counsel - 01/18/01
Corporate Officer/Principal 57 01/18/01

Members of the board

Members of the board TitleAgeSince
Director/Board Member 69 01/22/01
Director/Board Member 67 02/08/02
Chairman 53 02/08/02
Director/Board Member 63 01/18/01
Director/Board Member - 25/23/25
Director/Board Member 47 01/22/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 248,552,200 214,949,219 ( 86.48 %) 10,826,465 ( 4.356 %) 86.48 %

Shareholders

NameEquities%Valuation
Baillie Gifford & Co.
3.516 %
8,358,939 3.516 % 725 M €
PRIMECAP Management Co.
2.023 %
4,807,918 2.023 % 417 M €
Temasek Holdings Pte Ltd.
1.901 %
4,518,080 1.901 % 392 M €
Harding Loevner LP
1.659 %
3,944,474 1.659 % 342 M €
Flossbach von Storch AG
1.459 %
3,468,986 1.459 % 301 M €
BlackRock Institutional Trust Co. NA
0.6981 %
1,659,475 0.6981 % 144 M €
UBS AG (Investment Management)
0.4187 %
995,253 0.4187 % 86 M €
Capital Research & Management Co. (World Investors)
0.3967 %
943,116 0.3967 % 82 M €
Fidelity Management & Research Co. LLC
0.3510 %
834,390 0.3510 % 72 M €
Altrinsic Global Advisors LLC
0.2998 %
712,708 0.2998 % 62 M €
NameEquities%Valuation
ATS Beteiligungsverwaltung GmbH
43.08 %
104,049,145 43.08 % 9 022 M €
Ugur Sahin
17.10 %
41,295,728 17.10 % 3 581 M €
1,525,967 0.6318 % 132 M €
913,247 0.3781 % 79 M €
Sean Marett
0.3376 %
815,263 0.3376 % 71 M €
739,784 0.3063 % 64 M €
14,695 0.006084 % 1 M €
Jens Holstein
0.000671 %
1,620 0.000671 % 140 470 €
1,480 0.000613 % 128 331 €
Anja Morawietz
0.000099 %
240 0.000099 % 20 810 €

Holdings

NameEquities%Valuation
33,333,333 20.06% 135,999,999 $
1,917,437 8.29% 23,456,774 $

Company contact information

BioNTech SE

An der Goldgrube 12

55131, Mainz

+49 6131 9084 0

http://www.biontech.de
address BioNTech SE(22UA)
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW